In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

GSK has continued to beat my expectations as ... The company's oncology portfolio, consisting of Zejula, Blenrep, Jemperli, and Ojjaara/Omjjara, reported total sales of $450 million in the second ...

GSK is also working on expanding the label of marketed products like Nucala, Zejula and Jemperli into additional indications.

GSK has a strong portfolio of marketed drugs for oncology indications, including Jemperli (dostarlimab), Zejula (niraparib) and Ojjaara, which are approved for various cancer indications.

GSK reported adjusted earnings of 72 cents per ... registered impressive growth on the back of rising Jemperli and Zejula sales and the newly-launched Ojjaara. Sales in the United States rose ...

GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and ...

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...

GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage trial, keeping the drugmaker in the race to bring the technology to ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £16.50. The company’s shares closed last ...